CTLA4 and neoplasm: Immune checkpoint inhibition in melanoma relies on the use of antibodies blocking either the programmed cell death protein 1 (PD-1), for example Nivolumab and Pembrolizumab, preventing melanoma tumor cells from escaping toxic T-cell action, or antibodies targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), namely Ipilimumab, leading to prolonged T-cell activation and resulting in clonal expansion and enlarged T-cell repertoire.